Building a Foundation for Global Growth through R&D and New Business Development Subsidiaries
First written in FY2021-Q1. 10 of 21 entries say "Advanced", first in FY2021-Q2. Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In November 2023, we also established the “Premier Anti-Aging Lab” internally to integrate basic research and product development and develop unique products responding to customer needs with greater agility.」
Following the merger of the research and development subsidiary, we continued to position the in-house lab as the center of research and product development, investing ¥241 million in R&D during the fiscal year in new product and brand development in the skincare field. - FY2026-H1RestatedAnnual report
「R&D activities amounted to ¥88 million during the interim consolidated accounting period. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The company recorded ¥88 million in R&D activities, but stated that there was no material change in the status of those activities. - FY2025R&D expenses down; product development continuesAnnual report
「Total R&D expenses for the consolidated fiscal year amounted to ¥283 million. They primarily comprised R&D activities for the development of new products under the DUO, CANADEL and Clayence brands, as well as for new brands.」
R&D expenses decreased from ¥589 million in the previous fiscal year to ¥283 million, but development of new products and new brands under the major brands is continuing. - FY2025-H1RestatedAnnual report
「R&D activities amounted to ¥142 million during the interim consolidated accounting period. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
R&D expenses amounted to ¥142 million in the first half, with no material change in the status of R&D activities. - FY2024-Q3RestatedAnnual report
「The total amount of the Group's research and development activities during the first 3 quarters of the current consolidated fiscal year was ¥364 million. There were no material changes in the status of the Group's research and development activities during the same period.」
The filing states that total R&D activities for the cumulative third quarter amounted to ¥364 million, with no material change in the status of those activities. - FY2023AdvancedAnnual report
「Research and development expenses totaled ¥589.425 million in the current consolidated fiscal year. They mainly comprised research and development activities for new products under the 「DUO」, 「CANADEL」, and 「Clayence」 brands and for new brands.」
Research and development expenses increased from ¥432.218 million in the previous fiscal year to ¥589.425 million, and research and development of new products under the major brands and new brands continued. - FY2023-Q3RestatedAnnual report
「The total amount of the Group's research and development activities during the first 3 quarters of the current consolidated fiscal year was ¥376.948 million. There were no material changes in the status of the Group's research and development activities during the same period.」
The Company disclosed total research and development activities of ¥376.948 million for the first 3 quarters and stated that there were no material changes in their status. - FY2023-Q2RestatedAnnual report
「Research and development activities totaled ¥230.454 million during the first 2 quarters of the current consolidated fiscal year. There were no material changes in the status of the Group's research and development activities during the same period.」
The Company disclosed research and development activities of ¥230.454 million for the first 2 quarters and stated that there were no material changes in their status. - FY2023-Q1RestatedAnnual report
「Research and development activities totaled ¥127.804 million during the first quarter of the current consolidated fiscal year. There were no material changes in the status of the Group's research and development activities during the same period.」
The Company disclosed research and development activities of ¥127.804 million for the first quarter and stated that there were no material changes in their status. - FY2022AdvancedAnnual report
「Research and development expenses totaled ¥432.218 million in the current consolidated fiscal year. They mainly comprised research and development activities for new products under the 「DUO」, 「CANADEL」, 「CitraN」, 「Immuno」, and 「Clayence」 brands and for new brands. In addition, the consolidated subsidiary 「プレミア・ウェルネスサイエンス株式会社」 conducted joint research and development with Showa University and announced 「Koo」, a brand whose main ingredient is cannabinoids. It is also conducting joint research and development with The University of Tokyo.」
Research and development expenses increased to ¥432.218 million, and the Company announced 「Koo」, a brand whose main ingredient is cannabinoids, following joint research with Showa University. - FY2022-Q3RestatedAnnual report
「The total amount of the Group's research and development activities during the first 3 quarters of the current consolidated fiscal year was ¥310.167 million. There were no material changes in the status of the Group's research and development activities during the same period.」
Research and development activities totaled ¥310.167 million, with no material changes in the status of research and development activities disclosed. - FY2022-Q2RestatedAnnual report
「Research and development activities totaled ¥194.701 million during the first 2 quarters of the current consolidated fiscal year. There were no material changes in the status of the Group's research and development activities during the same period.」
Research and development activities totaled ¥194.701 million during the first 2 quarters, with no material changes in the status of research and development activities disclosed. - FY2022-Q1RestatedAnnual report
「Research and development activities totaled ¥80.179 million during the first quarter of the current consolidated fiscal year. There were no material changes in the status of the Group's research and development activities during the same period.」
Research and development activities totaled ¥80.179 million in the first quarter, with no material changes in the status of research and development activities disclosed. - FY2021AdvancedAnnual report
「Research and development expenses totaled ¥211.199 million in the current consolidated fiscal year. In addition, the consolidated subsidiary 「プレミア・ウェルネスサイエンス株式会社」 began joint research with National University Corporation The University of Tokyo and Showa University.」
The research and development subsidiary was included in consolidation, with annual research and development expenses of ¥211.199 million and joint research with The University of Tokyo and Showa University disclosed. - FY2021-Q3AdvancedAnnual report
「The total amount of the Group's research and development activities during the first 3 quarters of the current consolidated fiscal year was ¥118.060 million. During the same period, the consolidated subsidiary 「プレミア・ウェルネスサイエンス株式会社」 began the following joint research projects with universities. ① In March 2021, it began joint research with National University Corporation The University of Tokyo to develop new functional materials and commercialize products using mesenchymal stem cell culture supernatant. The project aims to establish high-quality anti-aging products using mesenchymal stem cell culture supernatant and elucidate its mechanisms by identifying active ingredients in the secreted components of the supernatant and verifying their effects. ② In April 2021, it began joint research with Showa University and a comprehensive collaboration aimed at commercialization using cannabinoids. The project aims to develop functional materials using cannabinoids and commercialize them in products, while contributing to the sound growth and development of the cannabinoid-based product market.」
Research and development activities totaled ¥118.060 million, and joint research began with The University of Tokyo on mesenchymal stem cell culture supernatant and with Showa University on cannabinoids, including collaboration aimed at commercialization. - FY2021-Q2AdvancedAnnual report
「From the second quarter of the current consolidated fiscal year, 「プレミア・ウェルネスサイエンス株式会社」 has been newly established and included in the scope of consolidation.」
The subsidiary responsible for research and development and new business development was included in the scope of consolidation, clarifying its role in Group operations following its establishment. - FY2021-Q1First statedAnnual report
「The Company recognizes that its future growth strategy requires enhancing brand value globally and reforming its business structure, and that, for customers to choose its products, products it develops and sells must be clearly superior to similar products in terms of quality, including efficacy and safety. Based on this recognition, the Company established the subsidiary 「プレミア・ウェルネスサイエンス株式会社」 to provide customers with high-quality products, promote research and development with global markets in mind, and explore new fields. 「プレミア・ウェルネスサイエンス株式会社」 is responsible for strengthening and complementing functions that the Company does not have, namely R&I (seed discovery), R&D (research and development), and BD (new business development). Through industry-academia-government collaboration, the subsidiary will discover new materials and technologies, obtain evidence of their effects and efficacy, and use the marketing expertise developed through the Company's existing brands to pursue commercialization and revenue generation in new businesses through low-cost operations with limited initial investment.」
A wholly owned subsidiary was established on 10 December 2020. With global markets in mind, it aims to complement the R&I, R&D, and BD functions and pursue commercialization and revenue generation in new businesses through industry-academia-government collaboration, discovery of new materials and technologies, acquisition of evidence, and use of the marketing expertise of existing brands.